世界の加齢黄斑変性症（AMD）治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5569 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、加齢黄斑変性症（AMD）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（ウェットAMD、ドライAMD）、用途別市場規模（病院、診療所、研究機関、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・加齢黄斑変性症（AMD）治療の市場動向 ・企業の競争状況、市場シェア ・加齢黄斑変性症（AMD）治療の種類別市場規模と予測2016-2027（ウェットAMD、ドライAMD） ・加齢黄斑変性症（AMD）治療の用途別市場規模と予測2016-2027（病院、診療所、研究機関、その他） ・加齢黄斑変性症（AMD）治療の北米市場規模2016-2027（アメリカ、カナダ） ・加齢黄斑変性症（AMD）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・加齢黄斑変性症（AMD）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・加齢黄斑変性症（AMD）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・加齢黄斑変性症（AMD）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Amgen Inc.、Bausch Health Companies, Inc.、F. Hoffmann-La Roche Ltd.、Novartis AG、Regeneron Pharmaceuticals Inc.） ・結論

Age-related macular degeneration is a bilateral ocular condition in which the central area of the retina, known as the macula, is affected.
Age-related macular degeneration is a progressive condition, and it is common among the geriatric population. The growing geriatric population is contributing to the rising incidence of age-related macular degeneration globally. As a result, there is a high demand for therapeutics to treat the condition. Pharmaceutical companies are leveraging this opportunity and are focusing on releasing drugs to treat age-related macular degeneration.

Market Analysis and Insights: Global Age-Related Macular Degeneration (AMD) Therapeutics Market
The global Age-Related Macular Degeneration (AMD) Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Age-Related Macular Degeneration (AMD) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Age-Related Macular Degeneration (AMD) Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Age-Related Macular Degeneration (AMD) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Age-Related Macular Degeneration (AMD) Therapeutics market.

Global Age-Related Macular Degeneration (AMD) Therapeutics Scope and Market Size
Age-Related Macular Degeneration (AMD) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Age-Related Macular Degeneration (AMD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Wet AMD
Dry AMD

Segment by Application
Hospital
Clinic
Research Institute
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen Inc.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
Novartis AG
Regeneron Pharmaceuticals Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Wet AMD
1.2.3 Dry AMD
1.3 Market by Application
1.3.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Research Institute
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Perspective (2016-2027)
2.2 Age-Related Macular Degeneration (AMD) Therapeutics Growth Trends by Regions
2.2.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Dynamic
2.3.1 Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
2.3.2 Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
2.3.3 Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
2.3.4 Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue
3.1.1 Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Age-Related Macular Degeneration (AMD) Therapeutics Revenue
3.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio
3.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2020
3.5 Age-Related Macular Degeneration (AMD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service
3.7 Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Type
4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2022-2027)

5 Age-Related Macular Degeneration (AMD) Therapeutics Breakdown Data by Application
5.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
6.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
6.2.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
6.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
6.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
6.4 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
6.4.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
7.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
7.2.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
7.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
7.3.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
7.4 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
7.4.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
8.2.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
8.3.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region
8.4.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
9.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
9.2.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
9.3.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
9.4.1 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
10.2.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
10.3.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country
10.4.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
11.1.4 Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 Bausch Health Companies, Inc.
11.2.1 Bausch Health Companies, Inc. Company Details
11.2.2 Bausch Health Companies, Inc. Business Overview
11.2.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
11.2.4 Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
11.2.5 Bausch Health Companies, Inc. Recent Development
11.3 F. Hoffmann-La Roche Ltd.
11.3.1 F. Hoffmann-La Roche Ltd. Company Details
11.3.2 F. Hoffmann-La Roche Ltd. Business Overview
11.3.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
11.3.4 F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
11.3.5 F. Hoffmann-La Roche Ltd. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Introduction
11.4.4 Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
11.4.5 Novartis AG Recent Development
11.5 Regeneron Pharmaceuticals Inc.
11.5.1 Regeneron Pharmaceuticals Inc. Company Details
11.5.2 Regeneron Pharmaceuticals Inc. Business Overview
11.5.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Introduction
11.5.4 Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Wet AMD
Table 3. Key Players of Dry AMD
Table 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2016-2021)
Table 8. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2022-2027)
Table 10. Age-Related Macular Degeneration (AMD) Therapeutics Market Trends
Table 11. Age-Related Macular Degeneration (AMD) Therapeutics Market Drivers
Table 12. Age-Related Macular Degeneration (AMD) Therapeutics Market Challenges
Table 13. Age-Related Macular Degeneration (AMD) Therapeutics Market Restraints
Table 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players (2016-2021)
Table 16. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2020)
Table 17. Ranking of Global Top Age-Related Macular Degeneration (AMD) Therapeutics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Age-Related Macular Degeneration (AMD) Therapeutics Product Solution and Service
Table 21. Date of Enter into Age-Related Macular Degeneration (AMD) Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2016-2021)
Table 25. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2016-2021)
Table 29. Global Age-Related Macular Degeneration (AMD) Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Amgen Inc. Company Details
Table 62. Amgen Inc. Business Overview
Table 63. Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
Table 64. Amgen Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
Table 65. Amgen Inc. Recent Development
Table 66. Bausch Health Companies, Inc. Company Details
Table 67. Bausch Health Companies, Inc. Business Overview
Table 68. Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
Table 69. Bausch Health Companies, Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
Table 70. Bausch Health Companies, Inc. Recent Development
Table 71. F. Hoffmann-La Roche Ltd. Company Details
Table 72. F. Hoffmann-La Roche Ltd. Business Overview
Table 73. F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product
Table 74. F. Hoffmann-La Roche Ltd. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
Table 75. F. Hoffmann-La Roche Ltd. Recent Development
Table 76. Novartis AG Company Details
Table 77. Novartis AG Business Overview
Table 78. Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product
Table 79. Novartis AG Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
Table 80. Novartis AG Recent Development
Table 81. Regeneron Pharmaceuticals Inc. Company Details
Table 82. Regeneron Pharmaceuticals Inc. Business Overview
Table 83. Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product
Table 84. Regeneron Pharmaceuticals Inc. Revenue in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021) & (US$ Million)
Table 85. Regeneron Pharmaceuticals Inc. Recent Development
Table 86. Research Programs/Design for This Report
Table 87. Key Data Information from Secondary Sources
Table 88. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Wet AMD Features
Figure 3. Dry AMD Features
Figure 4. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Research Institute Case Studies
Figure 8. Other Case Studies
Figure 9. Age-Related Macular Degeneration (AMD) Therapeutics Report Years Considered
Figure 10. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 11. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions: 2020 VS 2027
Figure 13. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Regions (2022-2027)
Figure 14. Global Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Players in 2020
Figure 15. Global Top Age-Related Macular Degeneration (AMD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Age-Related Macular Degeneration (AMD) Therapeutics as of 2020
Figure 16. The Top 10 and 5 Players Market Share by Age-Related Macular Degeneration (AMD) Therapeutics Revenue in 2020
Figure 17. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2016-2021)
Figure 18. Global Age-Related Macular Degeneration (AMD) Therapeutics Revenue Market Share by Type (2022-2027)
Figure 19. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 20. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
Figure 21. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
Figure 22. North America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
Figure 23. United States Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Canada Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
Figure 27. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
Figure 28. Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
Figure 29. Germany Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. France Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. U.K. Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Italy Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Russia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Nordic Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
Figure 37. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
Figure 38. Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Region (2016-2027)
Figure 39. China Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Japan Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. South Korea Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Southeast Asia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. India Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Australia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
Figure 47. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
Figure 48. Latin America Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
Figure 49. Mexico Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Brazil Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Type (2016-2027)
Figure 53. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Application (2016-2027)
Figure 54. Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Share by Country (2016-2027)
Figure 55. Turkey Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Saudi Arabia Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. UAE Age-Related Macular Degeneration (AMD) Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Amgen Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
Figure 59. Bausch Health Companies, Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
Figure 60. F. Hoffmann-La Roche Ltd. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
Figure 61. Novartis AG Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
Figure 62. Regeneron Pharmaceuticals Inc. Revenue Growth Rate in Age-Related Macular Degeneration (AMD) Therapeutics Business (2016-2021)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

---